Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

Results Announced Phase I/II Study of Deferiprone

A team of researchers from the “Medical Genetic Clinic and Research Unit” Inserm Unit 781 directed by Arnold Munnich (Necker - Sick Children’s Hospital, Paris) in collaboration with Ioav Cabantchik (Hebrew University, Jerusalem) have just obtained promising results for the treatment of neurological damage from Friedreich Ataxia, the most frequent of hereditary ataxias. Movement coordination, speech as well as certain sensory disorders were improved under the effect of deferiprone, a molecule which traps the iron accumulated abnormally in certain regions of the brain. These positive results, obtained right from phase I/II of the trail, offer short term therapeutic prospects for this severely disabling disease.

Read More: Results Announced Phase I/II Study of Deferiprone

About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedInYoutube
Family D.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News